Details from the source.
Source-listed Tirzepatide (SKU TR30): 30mg*10vials. PriceList(1).pdf lists 84 per 10 vials but does not specify currency; the website displays $84 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- TR30
- Source specification
- 30mg*10vials
- Source document
- PriceList(1).pdf, page 2
- Photograph
- Owner-supplied photograph; visible package label matched to this catalogue entry. Supplier identity, lot, and product quality have not been independently verified.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Tirzepatide is an engineered peptide based on the GIP sequence and modified to activate both GIP and GLP-1 receptors. It is genuinely a peptide. That scientific identity does not establish what is in any particular supplier vial. [1]
Biological mechanism
Tirzepatide selectively activates GIP and GLP-1 receptors. FDA labeling describes enhanced first- and second-phase insulin secretion and reduced glucagon levels in a glucose-dependent manner. It also delays gastric emptying and is associated with reduced food intake and body weight. [1] The thyroid C-cell tumors described in FDA labeling occurred in rats; human relevance is unknown, so this is an animal finding and not an established human effect. [1] [2]
Research focus
Human research has examined glucose control in type 2 diabetes, weight reduction and long-term weight maintenance in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. [1] [2] [3]
Potential applications in the evidence
The human evidence and U.S. labels concern glycemic control for type 2 diabetes, weight reduction/long-term weight maintenance in specified adults, and OSA in adults with obesity. These are investigated or approved uses of specified branded formulations, not proven applications of the catalogued vial. FDA notes the OSA improvement was likely related to weight reduction. [1] [2] [3]
Human evidence
In the 40-week, open-label phase 3 SURPASS-2 trial, 1,879 adults with type 2 diabetes were randomized to tirzepatide or semaglutide; the study reported improvements in glycated hemoglobin and greater weight reduction in the tirzepatide groups. [5] The 72-week, placebo-controlled SURMOUNT-1 trial studied 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, and reported greater mean weight reduction in tirzepatide groups than placebo. [4] FDA’s OSA approval announcement describes two randomized, placebo-controlled 52-week studies involving 469 adults with obesity and OSA without type 2 diabetes. [3] These findings are for defined trial products and study populations; they do not establish equivalence, efficacy, purity, or safety of an unidentified supplier vial.
Known and potential effects
FDA labeling lists nausea, diarrhea, vomiting, constipation, abdominal discomfort or pain, dyspepsia and decreased appetite among commonly reported adverse reactions. Other reported or potential effects include severe gastrointestinal reactions, acute pancreatitis, gallbladder disease, dehydration-related acute kidney injury, serious hypersensitivity and hypoglycemia, especially when combined with insulin or insulin secretagogues. [1] [2]
Safety and contraindications
FDA labels warn about severe gastrointestinal reactions, pancreatitis, gallbladder disease, dehydration-related kidney injury, serious hypersensitivity, hypoglycemia with insulin or insulin secretagogues, delayed gastric emptying and possible effects on oral medicines, and aspiration reported during general anesthesia or deep sedation. They warn of possible fetal harm and contraindicate the approved products for people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or serious hypersensitivity to tirzepatide or product excipients. Use is not recommended in severe gastroparesis. These label warnings describe FDA-approved formulations and do not verify the composition or risk of the listed vial. [1] [2]
U.S. FDA / regulatory status
As of 2026-10-30, FDA-approved branded formulations containing tirzepatide include Mounjaro, labeled to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, and Zepbound, labeled for weight reduction/long-term maintenance in specified adults and for moderate-to-severe OSA in adults with obesity. [1] [2] Approval of an active ingredient or branded formulation does not transfer to this supplier-specific item. The supplied catalogue gives no manufacturer, finished formulation, source, jurisdiction, authorization number, or lot; therefore approval of the exact catalogued vial cannot be verified. No claim is made that the vial is compounded or research-only.
Evidence limitations
Human trials studied defined products, populations, endpoints and follow-up periods; their findings cannot establish the identity, quality, efficacy, or safety of this exact supplier vial. The rodent thyroid C-cell finding has unknown human relevance. Trial results and approved-product safety information do not establish the safety or efficacy of every tirzepatide-containing preparation or resolve every rare or long-term risk. [1] [2] [4] [5]
Supporting sources
- MOUNJARO Prescribing Information U.S. Food and Drug Administration · FDA prescribing information. Supports: Peptide description, dual GIP/GLP-1 receptor mechanism, Mounjaro labeled indication, contraindications, warnings and adverse reactions.
- ZEPBOUND Prescribing Information U.S. Food and Drug Administration · FDA prescribing information. Supports: Zepbound labeled indications for weight reduction/maintenance and OSA, plus contraindications, warnings and adverse reactions.
- FDA Approves First Medication for Obstructive Sleep Apnea U.S. Food and Drug Administration · Regulatory press announcement. Supports: U.S. OSA approval and supporting human studies; safety summary and FDA statement that OSA improvement likely relates to weight reduction.
- Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine · Peer-reviewed phase 3 clinical trial. Supports: SURMOUNT-1 trial design, studied population, 72-week human weight outcomes and reported adverse events.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes U.S. National Library of Medicine, PubMed · Peer-reviewed phase 3 clinical trial record and abstract. Supports: SURPASS-2 trial design, 40-week human glycemic and weight outcomes, and adverse events.